title: Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
abstract: Kidney transplant recipients are prone to hypertension, dyslipidemia, and cardiovascular death. Hypertension is associated with hemostatic abnormalities. Thrombin activatable fibrinolysis inhibitor (TAFI) is a glycoprotein that links coagulation and fibrinolysis. The purpose of this study was to assess TAFI concentrations in renal transplant recipients in relation to blood pressure. Additionally, we evaluated thrombin activity (thrombin-antithrombin complex [TAT], prothrombin fragments 1+2 [F1+2]), thrombomodulin (TM), and the degree of plasmin generation (plasmin-antiplasmin complex [PAP]) using commercially available kits. The studies were performed on 86 renal allograft recipients (48 women, 38 men) at age range 26 to 73 years. The immunosuppressive regimen consisted of cyclosporine (CsA), prednisone, and azathioprine (n = 58) or mycophenolate mofetil (MMF; n = 28). All patients maintained sufficient and stable graft function, showing no clinical signs of rejection. In patients with hypertension (n = 68), we observed significantly higher concentrations of TAFI and of markers of thrombin generation (F1+2, TAT), and of thrombomodulin with significantly prolonged euglobulin clot lysis time (ECLT), which reflects overall fibrinolytic activity and lower fibrinolytic activity index (FAI). Both groups did not differ with respect to age, creatinine clearance, body mass index, time after transplantation, albumin, fibrinogen, and PAP. Diastolic blood pressure correlated significantly with TAFI concentrations, uric acid, and prednisone dose, whereas systolic blood pressure correlated with urea, uric acid, creatinine clearance, and MCV. Elevated TAFI concentrations and enhanced thrombin generation in hypertensive kidney transplant recipients may contribute to the hypofibrinolysis and progressive atherosclerosis in this population. Blood pressure was related to kidney function, maintenance prednisone dose, and TAFI concentration.
authors.affiliation: Department of Nephrology and Transplantology, Bialystok Medical University, ul. Zurawia 14, 15-540 Bialystok, Poland. jolmal@poczta.onet.pl
authors.forename: J
authors.initials: J
authors.lastname: Malyszko
authors.forename: J S
authors.initials: JS
authors.lastname: Malyszko
authors.forename: T
authors.initials: T
authors.lastname: Hryszko
authors.forename: M
authors.initials: M
authors.lastname: Mysliwiec
mesh_terms: D000328:Adult; D000368:Aged; D000991:Antithrombins / Q000032:analysis; D001777:Blood Coagulation / Q000502:physiology; D025901:Carboxypeptidase B2 / Q000097:blood*; D004359:Drug Therapy, Combination; D005260:Female; D005342:Fibrinolysis / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000097:blood*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation / Q000503:physiopathology; D016030:Kidney Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D013917:Thrombin / Q000032:analysis
chemical_list: D000991:Antithrombins; D007166:Immunosuppressive Agents; D025901:Carboxypeptidase B2; D013917:Thrombin